Electronic Acknowledgement Receipt				
EFS ID:	5204668			
Application Number:	10670915			
International Application Number:				
Confirmation Number:	6525			
Title of Invention:	1,3,5-Triazines for treatment of viral diseases			
First Named Inventor/Applicant Name:	Richard Daifuku			
Customer Number:	20350			
Filer:	Alexander Reed Trimble/Linda Lim			
Filer Authorized By:	Alexander Reed Trimble			
Attorney Docket Number:	021227-000310US			
Receipt Date:	23-APR-2009			
Filing Date:	24-SEP-2003			
Time Stamp:	13:44:51			
Application Type:	Utility under 35 USC 111(a)			

Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	\$180
RAM confirmation Number	39
Deposit Account	201430
Authorized User	

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

Charge any Additional Fees required under 37 C.F.R. Section 1.19 (Document supply fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.21 (Miscellaneous fees and charges)

File Listing	g:				
Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1 Miscellaneous Incoming Letter	Transmittal.pdf	59527	no	1	
		5957a297af06c81d0090b4f30d82df1b053e b049			
Warnings:					
Information:					
2 Transmittal Letter	Supplemental_IDS_Cover_Lett	76116	no	2	
		er.pdf	b9169ffce7a2ba372eeeaf2222de61d2b2e4 4394		
Warnings:					
Information:					
3	Information Disclosure Statement (IDS) Filed (SB/08)	Supplemental_IDS.pdf	72026	no	1
			8c5e8aa7143e24ea2010a7052af286af80ed 1177		
Warnings:					
Information:					
This is not an U	SPTO supplied IDS fillable form				
4	Foreign Reference	021227_000310US_WO_95_28 940.pdf	728984	no	17
	1 Toreign Neiterenee		185fb563ba88a9e3232b0939b01180415af 24b57		
Warnings:					
Information:					
5	5 NPL Documents 021227_000310U earch_Labora	021227_000310US_Merck_Res	758705	no	6
		earch_Laboratories.pdi	28e456837797dace801c4ec19308864b7fd 972e3		
Warnings:					
Information:					
6	6 NPL Documents	021227_000310US_Poizot_Mar tin_et_al.pdf	547653	no	7
			f7af0fb176aea7f20b023898e365b551181d 22fa		
Warnings:					
Information:					
7 NPL Documents	021227_000310US_Yokota_et_ al.pdf	570451	no	5	
		f3b2dedd8082a79b7c665667e3b786a22c1 d6b6c			
Warnings:					
Information:					
	Fee Worksheet (PTO-875)	fee-info.pdf	29915	no	2
			5836c2f5a3c8c9ce0df0c184d6249c64c1de 4d86		
Warnings:					
Information:					

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.